Journal of Diagnostics Concepts & Practice ›› 2016, Vol. 15 ›› Issue (06): 573-577.doi: 10.16150/j.1671-2870.2016.06.006
• Experts forum • Previous Articles Next Articles
Received:2016-11-14
Online:2016-12-25
Published:2022-07-27
CLC Number:
| [1] Matarazzo MR, De Bonis ML, Strazzullo M, et al.Multiple binding of methyl-CpG and polycomb proteins in long-term gene silencing events[J]. J Cell Physiol,2007, 210(3):711-719. [2] Fandy TE, Herman JG, Kerns P, et al.Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies[J]. Blood,2009, 114(13):2764-2773. [3] Palii SS, Van Emburgh BO, Sankpal UT, et al.DNA methylation inhibitor 5-Aza-2'-deoxycytidine induces reversible genome-wide DNA damage that is distinctly influenced by DNA methyltransferases 1 and 3B[J]. Mol Cell Biol,2008,28(2):752-771. [4] Mortusewicz O, Schermelleh L, Walter J, et al.Recruitment of DNA methyltransferase I to DNA repair sites[J]. Proc Natl Acad Sci U S A,2005,102(25):8905-8909. [5] Aimiuwu J, Wang H, Chen P, et al.RNA-dependent inhibition of ribonucleotide reductase is a major pathway for 5-azacytidine activity in acute myeloid leukemia[J]. Blood, 2012,119(22):5229-5238. [6] Liu K, Wang YF, Cantemir C, et al.Endogenous assays of DNA methyltransferases: Evidence for differential activities of DNMT1, DNMT2, and DNMT3 in mammalian cells [7] Bejar R, Lord A2, Stevenson K, et al. TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients[J]. Blood,2014,124(17):2705-2712. [8] Giachelia M, D'Alò F, Fabiani E, et al. Gene expression profiling of myelodysplastic CD34+ hematopoietic stem cells treated [9] Desmond JC, Raynaud S, Tung E, et al.Discovery of epigenetically silenced genes in acute myeloid leukemias[J]. Leukemia,2007,21(5):1026-1034. [10] Li H, Chiappinelli KB, Guzzetta AA, et al.Immune re-gulation by low doses of the DNA methyltransferase inhibitor 5-azacitidine in common human epithelial cancers[J]. Oncotarget,2014,5(3):587-598. [11] Goodyear OC, Dennis M, Jilani NY, et al.Azacitidine augments expansion of regulatory T cells after allogeneic stem cell transplantation in patients with acute myeloid leukemia (AML)[J]. Blood,2012,119(14):3361-3369. [12] Bryan J, Jabbour DE,Prescott H, et al.Current and future management options for myelodysplastic syndromes[J].Drugs,2010,70(11):138l-1394. [13] Lee JH, Choy ML, Ngo L,et al.Histone deacetylase inhibitor induces DNA damage, which normal but not transformed cells can repair[J]. Proc Natl Acad Sci U S A,2010,107(33):14639-14644. [14] Taby R, Issa JP.Cancer epigenetics[J]. CA Cancer J Clin,2010,60(6):376-392. [15] Voso MT, Santini V, Finelli C, et al.Valproic acid at therapeutic plasma levels may increase 5-azacytidine efficacy in higher risk myelodysplastic syndromes[J]. Clin Cancer Res,2009,15(15):5002-5007. [16] Issa JP, Garcia-Manero G, Huang X, et al.Results of phase 2 randomized study of low-dose decitabine with or without valproic acid in patients with myelodysplastic syndrome and acute myelogenous leukemia[J]. Cancer,2015,121(4): 556-561. [17] Prebet T, Vey N.Vorinostat in acute myeloid leukemia and myelodysplastic syndromes[J]. Expert Opin Investig Drugs,2011,20(2):287-295. [18] Bertino EM, Otterson GA.Romidepsin: a novel histone deacetylase inhibitor for cancer[J]. Expert Opin Investig Drugs,2011,20(8):1151-1158. [19] Jabbour E, Garcia-Manero G.Deacetylase inhibitors for the treatment of myelodysplastic syndromes[J]. Leuk Lymphoma,2015,56(5):1205-1212 [20] Dutt S, Narla A, Lin K, et al.Haploinsufficiency for ribosomal protein genes causes selective activation of p53 in human erythroid progenitor cells[J]. Blood,2011,117(9):2567-2576. [21] Wei S, Chen X, McGraw K, et al. Lenalidomide promotes p53 degradation by inhibiting MDM2 auto-ubiquitination in myelodysplastic syndrome with chromosome 5q deletion[J]. Oncogene,2013,32(9):1110-1120. [22] Starczynowski DT, Kuchenbauer F, Argiropoulos B, et al.Identification of miR-145 and miR-146a as mediators of the 5q- syndrome phenotype[J]. Nat Med,2010,16(1):49-58. [23] Venner CP, Woltosz JW, Nevill TJ, et al.Correlation of clinical response and response duration with miR-145 induction by lenalidomide in CD34(+) cells from patients with del(5q) myelodysplastic syndrome[J]. Haematologica,2013,98(3):409-413. [24] Wei S, Chen X, Rocha K, et al.A critical role for phosphatase haplodeficiency in the selective suppression of deletion 5q MDS by lenalidomide[J]. Proc Natl Acad Sci U S A,2009,106(31):12974-12979. [25] Schneider RK, Ademà V, Heckl D, et al.Role of casein kinase 1A1 in the biology and targeted therapy of del(5q) MDS[J]. Cancer Cell,2014,26(4):509-520. [26] Fink EC, Ebert BL.The novel mechanism of lenalidomide activity[J]. Blood,2015,126(21):2366-2369. [27] Yip BH, Pellagatti A, Vuppusetty C, et al.Effects of L-leucine in 5q- syndrome and other RPS14-deficient erythroblasts[J]. Leukemia,2012,26(9):2154-2158. [28] Caceres G, McGraw K, Yip BH, et al. TP53 suppression promotes erythropoiesis in del(5q) MDS, suggesting a targeted therapeutic strategy in lenalidomide-resistant patients[J]. Proc Natl Acad Sci U S A,2013,110(40):16127-16132. [29] Narla A, Dutt S, McAuley JR, et al. Dexamethasone and lenalidomide have distinct functional effects on erythropoiesis[J]. Blood,2011,118(8):2296-2304. [30] Ximeri M, Galanopoulos A, Klaus M, et al.Effect of lenalidomide therapy on hematopoiesis of patients with myelodysplastic syndrome associated with chromosome 5q deletion[J]. Haematologica,2010,95(3):406-414. [31] Garcia-Manero G, Fenaux P, Al-Kali A, et al.Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethyla-ting drugs(ONTIME): a randomised, controlled, phase 3 trial[J]. Lancet Oncol,2016,17(4):496-508. [32] Yang H, Bueso-Ramos C, DiNardo C, et al. Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents[J]. Leukemia,2014,28(6):1280-1288. [33] Mies A, Hermine O, Platzbecker U.Activin Receptor Ⅱ Ligand Traps and Their Therapeutic Potential in Myelodysplastic Syndromes with Ring Sideroblasts[J]. Curr Hematol Malig Rep,2016. [34] Benetatos CA, Mitsuuchi Y, Burns JM, et al.Birinapant (TL32711), a bivalent SMAC mimetic, targets TRAF2-associated cIAPs, abrogates TNF-induced NF-κB activation, and is active in patient-derived xenograft models[J]. Mol Cancer Ther,2014,13(4):867-879. |
| [1] | . [J]. Journal of Diagnostics Concepts & Practice, 2020, 19(02): 195-198. |
| [2] | . [J]. Journal of Diagnostics Concepts & Practice, 2019, 18(06): 685-671. |
| [3] | . [J]. Journal of Diagnostics Concepts & Practice, 2017, 16(05): 468-471. |
| [4] | CAO Yafeng, WANG Jing, GU Jun, LU Hongyu, XUN Jie, LIU Yuanfang, WANG Yan, WANG Jin, CHEN Yu, CHEN Yubao, LI Jiaming, HAO Jie, MI Jianqing, CHEN Mei. Analysis of peripheral neuropathy following treatment with bortezomib in 114 newly-diagnosed multiple myeloma patients [J]. Journal of Diagnostics Concepts & Practice, 2017, 16(05): 492-497. |
| [5] | . [J]. Journal of Diagnostics Concepts & Practice, 2017, 16(05): 472-476. |
| [6] | . [J]. Journal of Diagnostics Concepts & Practice, 2017, 16(05): 455-459. |
| [7] | . [J]. Journal of Diagnostics Concepts & Practice, 2016, 15(06): 545-549. |
| [8] | . [J]. Journal of Diagnostics Concepts & Practice, 2016, 15(06): 556-560. |
| [9] | . [J]. Journal of Diagnostics Concepts & Practice, 2016, 15(06): 561-566. |
| [10] | . [J]. Journal of Diagnostics Concepts & Practice, 2016, 15(06): 567-572. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||
